Opko acquires Aquashunt maker

Article

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Aquashunt is an implantable device designed to reduce intraocular pressure physiologically. Currently in the preclinical stage, in vivo studies are anticipated to commence towards the end of the year.

"We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business, providing us with the potential to market an innovative product that addresses a serious disease affecting millions of people," said Dr Naveed Shams, Chief Medical Officer and Senior Vice President of Research and Development of OPKO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Related Content
Tepezza receives marketing authorisation from MHRA

Tepezza receives marketing authorisation from MHRA

Kassi Filkins
May 8th 2025
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of Salt Lake City. Historic downtown area. Concept image for 2025 Association for Research in Vision and Ophthalmology (ARVO). Image credit: ©pabrady63 – stock.adobe.com

Editorial Advisory Board members bring research findings to ARVO

Sydney M Crago
May 5th 2025
Article

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

An image of an eye behind glasses. Digital input on the glasses conveys concept of artificial intelligence and computing. Image credit: ©Arsenii – stock.adobe.com

ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership

Martin David Harp
May 2nd 2025
Article

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

LuxIA receives CE-MDR certification

LuxIA receives CE-MDR certification

Sydney M Crago
May 1st 2025
Article

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

An image of a map of Europe with lights all over the surface. Concept image for European Medicines Agency, European Commission approval of Thyroid Eye Disease medication. Image credit: ©Pickoloh – stock.adobe.com

EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application

Hattie Hayes
April 30th 2025
Article

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment

© 2025 MJH Life Sciences

All rights reserved.